ad 20

AD 20 is designed to reduce toxicity. It also enhances the activity of anticancer drugs.

BChE/MAO-B-IN-1 is a dual inhibitor of BChE and MAO-B, with IC50 values of 375 nM and 20 nM, respectively. It effectively counteracts oxidative damage induced by H2O2 and 6-OHDA in SH-SY5Y cells and can penetrate the central nervous system in cell models simulating the blood-brain barrier. BChE/MAO-B-IN-1 is applicable for research into neurological disorders such as Alzheimer's disease (AD).

Multitarget AD inhibitor-2 (Compound VN-19) is a versatile inhibitor targeting multiple sites, acting on acetylcholinesterase (AChE, IC50 = 0.14 μM), butyrylcholinesterase (BChE, IC50 = 11.6 μM), and monoamine oxidase B (MAO B, IC50 = 0.45 μM). It inhibits amyloid-beta protein Aβ1-42 self-induced aggregation with an inhibition rate of 47.3% at 20 μM and reduces ROS levels in SH-SY5Y cells with an inhibition rate of 80% at 25 μM. Multitarget AD inhibitor-2 can also improve cognitive decline in a scopolamine-induced Alzheimer's zebrafish model.

Q134R, a neuroprotective derivative of hydroxyquinoline, effectively inhibits nuclear factor of activated T-cell (NFAT) signaling and possesses the ability to cross the blood-brain barrier. This compound shows promise for research into Alzheimer's disease (AD) and aging-related disorders[1].

BChE-IN-8 (compound 20) is an orally active butyrylcholinesterase (BChE) inhibitor that crosses the blood-brain barrier, targeting eqBChE (IC50: 0.15 nM) and hBChE (IC50: 45.2 nM). It is used in Alzheimer's disease (AD) research for its neuroprotective and cognitive improvement effects, affecting the cholinergic system, Aβ aggregation, and neuropeptide levels.

AChE/BACE1/GSK3β-IN-1 is an orally active, blood-brain barrier-permeable, moderately bioavailable triple inhibitor of AChE, BACE1, and GSK3β, utilized for Alzheimer's disease (AD) research.

PDE5-IN-10 (compound 4b), a potent phosphodiesterase type 5 (PDE5) inhibitor, exhibits an effective half-maximal inhibitory concentration (IC50) of 20 nM, enhanced in vitro microsomal stability (t 1/2 = 44.6 min), and excellent efficacy in restoring long-term potentiation, making it suitable for Alzheimer's disease (AD) research [1].